scholarly journals Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 ◽  
Vol 14 (22) ◽  
pp. 7272-7283 ◽  
Author(s):  
Dana D. Hu-Lowe ◽  
Helen Y. Zou ◽  
Maren L. Grazzini ◽  
Max E. Hallin ◽  
Grant R. Wickman ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinases ◽  
Receptor Tyrosine Kinases ◽  
Growth Factor Receptor ◽  
Selective Inhibitor ◽  
Vascular Endothelial ◽  
Antitumor Activities ◽  
Endothelial Growth Factor

scholarly journals Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6

2015 ◽  
Vol 35 (4) ◽  
Author(s):  
Yvonne Volz ◽  
David Koschut ◽  
Alexandra Matzke-Ogi ◽  
Marina S. Dietz ◽  
Christos Karathanasis ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinases ◽  
Receptor Tyrosine Kinases ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Binding Affinities ◽  
Direct Binding ◽  
Endothelial Growth Factor ◽  
Hepatocyte Growth

CD44v6 is a co-receptor for the receptor tyrosine kinases Met and VEGFR-2 (vascular endothelial growth factor receptor 2). The binding of these RTKs (receptor tyrosine kinases) to their ligands on cells requires CD44v6. Pull-downs assays show direct binding between these entities. Binding affinities were measured by several biophysical methods.

Sign in / Sign up

Export Citation Format

Share Document